Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial
입원 중인 COVID-19 환자의 회복기 혈장 사용의 안전성과 효능을 평가하기 위한 무작위 임상 시험(PERUCONPLASMA): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
ABO blood type
Acute coronary syndrome
administration
Adverse reaction
Adverse reactions
aliquot
Aliquots
All participants
allocation
anaphylaxis
antibody
Antigen
assessment
Bilirubin
Blinding
block
blocks
blood gas
blood gas analysis
blood type
C-reactive protein
calculated
Capacity
carried
case report form
clinical
clinical trial
clinical trials
Coagulation
Coma
completion
confidence level
congestive heart failure
contraindication
control group
convalescent plasma
coronary syndrome
COVID-19
COVID-19 disease
COVID-19 pneumonia
creatinine
Critical
Critical disease
CRP
current
D-dimer
decrease
defined
detect
Diagnosis
dialysis
disease
Disseminated intravascular coagulation
dissemination
Donor
donors
drop
Duration
Dynamics
eCRF
Efficacy
electronic case report form
element
eligible
enrolled
enrolment
etiology
evaluate
evaluated
events
Evolution
exclusion criteria
expected
experimental group
exploratory
failure
following
gas analysis
hemodynamic instability
hemorrhage
hospital
hospital discharge
Hospitalization
Hospitalized
hospitalized patient
hospitalized patients
Hypothesis
Hypoxemia
ICU
IIb
in-hospital mortality
Inclusion
Infarction
Inflammatory
information
Informed consent
intensive care
intensive care unit
Intervention
intracranial hemorrhage
intravascular coagulation
Invasive mechanical ventilation
investigator
investigators
jaundice
Laboratory
laboratory confirmation
Laboratory test
Lactate
lactate dehydrogenase
Length
less
Local
lymphocyte
male
marker
Mechanical
mechanical ventilation
mmHg
molecular
Mortality
multi-organ failure
Myocardial infarction
Neutralizing antibodies
number
objective
occur
Older
open
open label
outcome
oxygen
Oxygen requirement
oxygen saturation
PaO
participant
Patient
performed
plasma
Platelets
Pneumonia
power
power of 80%
previous diagnosis
Probability
protocol
Public Hospital
public hospitals
quantification
randomization
Randomized
Randomized controlled trial
rationale
receive
reduce
reducing
reduction
Registered
resolution of symptom
respiratory
respiratory rate
routine clinical practice
Safe
Safety
Sample size
SARS-COV-2 infection
score
Secondary objectives
serious adverse reaction
Serious adverse reactions
serologic
serum
serum creatinine
severe COVID-19
Severe COVID-19 pneumonia
severe disease
SOFA
specific type
standard treatment
standard treatment alone
statistical analysis
Study protocol
Stupor
subject
supplementary material
Total
total bilirubin
transfusion
treatment arm
Trial
uncontrolled
vasopressors
Ventilation
website
with COVID-19
[DOI] 10.1186/s13063-021-05189-6 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05189-6 PMC 바로가기 [Article Type] Letter